Share Email Print

Proceedings Paper

Capecitabine (Xeloda) enhanced photodynamic therapy for treatment of breast cancer and its metastases in a murine breast tumor model (Conference Presentation)

Paper Abstract

Breast cancer (BCA) in women is a leading cause of mortality and morbidity with distant metastases occurring in ~40% of cases. Here, as an alternative to ionizing radiation therapy and chemotherapy and their associated side effects, we explored a new combination approach using capecitabine (CPBN) and aminolevulinate-based photodynamic therapy (PDT). We have recently shown that a combination PDT approach in which 5-fluorouracil (5FU), a differentiation-promoting agent, increases the levels of PpIX in cancer cells when given as a neoadjuvant prior to ALA. However, 5FU can be toxic when administered systemically at high levels. We reasoned that CPBN, a known chemotherapeutic drug for BCA and less toxic than 5FU (because CPBN is metabolized to 5FU specifically within tumor tissues), might work equally well as a PDT neoadjuvant. Murine 4T1 BCA cells harboring a luciferase transgene were injected into breast fat pads of female nude mice. CPBN (600 mg/kg/day) was administered by oral gavage for 3 days followed by intraperitoneal ALA administration and PDT with red light (633 nm) on day 4. Tumor growth and regression were monitored in vivo using bioluminescence imaging. Histological changes in primary tumors and metastases were assessed after necropsy. CPBN pretreatment of 4T1 tumors increased cellular differentiation, reduced proliferation, raised PpIX levels, enhanced tumor cell death, and reduced metastatic spread (incidence and tumor load) of 4T1 cells post-PDT, relative to vehicle-only controls. The use of CPBN as a non-toxic PDT neoadjuvant for treatment of BCA represents a novel approach with significant potential for translation into the clinic.

Paper Details

Date Published: 14 August 2019
Proc. SPIE 11070, 17th International Photodynamic Association World Congress, 110702E (14 August 2019); doi: 10.1117/12.2525564
Show Author Affiliations
Sanjay Anand, Cleveland Clinic (United States)
Anton Yasinchak, Cleveland Clinic (United States)
Taylor Bullock, Cleveland Clinic (United States)
Mukul Govande, Cleveland Clinic (United States)
Edward Maytin, Cleveland Clinic (United States)

Published in SPIE Proceedings Vol. 11070:
17th International Photodynamic Association World Congress
Tayyaba Hasan, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?